Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Analyst Ratings Changes
EW has been the subject of several recent analyst reports. Morgan Stanley lowered their target price on shares of Edwards Lifesciences from $136.00 to $119.00 and set an "overweight" rating for the company in a research note on Friday, July 15th. William Blair reaffirmed an "outperform" rating on shares of Edwards Lifesciences in a research note on Tuesday, April 26th. Stifel Nicolaus lowered their target price on shares of Edwards Lifesciences from $128.00 to $115.00 in a research note on Monday, July 18th. Cowen lowered their target price on shares of Edwards Lifesciences from $140.00 to $125.00 in a research note on Monday, July 11th. Finally, Canaccord Genuity Group cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating and reduced their price target for the company from $115.00 to $106.00 in a report on Friday, July 29th. Three research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $126.19.
Edwards Lifesciences Price Performance
EW Stock remained flat at $104.80 during trading hours on Monday. 28,239 shares of the company's stock were exchanged, compared to its average volume of 2,702,086. The company has a market capitalization of $64.97 billion, a PE ratio of 45.37, a PEG ratio of 3.09 and a beta of 1.12. The company has a quick ratio of 2.60, a current ratio of 3.37 and a debt-to-equity ratio of 0.10. The company's fifty day moving average is $97.80 and its 200-day moving average is $105.03. Edwards Lifesciences has a 12-month low of $85.58 and a 12-month high of $131.73.
Edwards Lifesciences (NYSE:EW - Get Rating) last announced its quarterly earnings results on Thursday, July 28th. The medical research company reported $0.63 EPS for the quarter, missing analysts' consensus estimates of $0.64 by ($0.01). The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 27.18% and a return on equity of 24.77%. The business's revenue was down .2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.64 EPS. On average, sell-side analysts forecast that Edwards Lifesciences will post 2.51 EPS for the current fiscal year.
Insider Activity
In other news, CEO Michael A. Mussallem sold 19,875 shares of the stock in a transaction dated Tuesday, June 14th. The shares were sold at an average price of $86.96, for a total value of $1,728,330.00. Following the transaction, the chief executive officer now directly owns 157,353 shares of the company's stock, valued at $13,683,416.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Michael A. Mussallem sold 19,875 shares of the stock in a transaction dated Tuesday, June 14th. The shares were sold at an average price of $86.96, for a total value of $1,728,330.00. Following the transaction, the chief executive officer now directly owns 157,353 shares of the company's stock, valued at $13,683,416.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daveen Chopra sold 1,000 shares of the stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $98.31, for a total transaction of $98,310.00. Following the completion of the transaction, the vice president now directly owns 19,911 shares in the company, valued at $1,957,450.41. The disclosure for this sale can be found here. Insiders have sold 81,062 shares of company stock valued at $7,656,531 over the last ninety days. 1.29% of the stock is currently owned by company insiders.
